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Abstract 63 
Purpose: To assess sampling bias in national viral suppression (VS) estimates derived from the Medical 64 
Monitoring Project (MMP) resulting from use of an abbreviated (four-month) annual sampling period. We aimed 65 
to improve VS estimates using cohort data from the North American AIDS Cohort Collaboration on Research and 66 
Design (NA-ACCORD) and a novel cohort-adjustment method. 67 
Methods: Using full calendar years of NA-ACCORD data, we assessed timing of HIV care attendance (inside 68 
versus exclusively outside MMP’s four-month sampling period), VS status at last test (<200 vs. ≥200 copies/mL), 69 
and associated demographics. These external estimates were used to standardize MMP to NA-ACCORD data 70 
with multivariable regression models of care attendance andVS , yielding adjusted 2009–2013 VS estimates with 71 
95% confidence intervals (CI). 72 
Results: Weighted percentages of VS among persons in HIV care were 67% in 2009 and 77% in 2013. These 73 
estimates are slightly lower than previously published MMP estimates (72% and 80% in 2009 and 2013, 74 
respectively). The number of persons receiving HIV care was previously underestimated by 20%, because 75 
patients receiving care exclusively outside the MMP sampling period did not contribute toward the weighted 76 
population estimate.  77 
Conclusions: Careful examination of national surveillance estimates using data triangulation and novel 78 
methodologies can improve the robustness of VS estimates. 79 
Keywords: HIV viral suppression, HIV clinical care, surveillance, indirect standardization 80 
 81 
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Introduction 84 
Sustained viral suppression (VS), which can beachieved through consistent use of antiretroviral therapy (ART), 85 
greatly improves health 1 and life expectancy 2 for persons living with HIV, while effectively eliminating HIV 86 
transmission risk 3,4. Monitoring population-level VS is important for demonstrating progress toward reaching 87 
national goals of improving the health of persons living with HIV and reducing new infections 5. The Centers for 88 
Disease Control and Prevention (CDC) has used two sources of surveillance data to measure VS. The Medical 89 
Monitoring Project (MMP) is a surveillance system that provides data to estimate VS among persons in HIV care, 90 
and the National HIV Surveillance System (NHSS) provides data to measure VS among persons with diagnosed 91 
HIV in a subset of jurisdictions.  92 
MMP collects behavioral and clinical data from annual, cross-sectional samples of persons living with diagnosed 93 
HIV using interviews and medical record abstraction 6. During 2009–2015, MMP described U.S. adults in HIV 94 
clinical care by sampling U.S. jurisdictions and territories, followed by HIV clinical care facilities within those 95 
jurisdictions, then persons seeking care within those facilities during January – April of a given year. The January 96 
– April sampling period was used to expedite data collection for annual estimates, and at the time of MMP’s 97 
inception, this sampling period captured 88% of adults in clinical care 7. This coverage estimate has not been 98 
reassessed. 99 
Surveillance estimates should be periodically revisited in light of temporal changes and methodological 100 
advances. One important temporal change over MMP’s lifespan is that the recommended number of clinical 101 
visits to monitor virologic response for persons on ART has decreased over time 8. As a result, persons engaged 102 
in HIV clinical care during a given year may be less likely to seek care during the four-month sampling period, 103 
and thus less likely to be sampled for MMP. The result of this sampling bias would be an underestimated 104 
weighted population size of persons receiving HIV clinical care and possibly biased estimates of the number and 105 
percentage of persons in HIV care with VS. 106 
We previously published findings from MMP indicating VS among persons in HIV clinical care increased from 107 
72% to 80% during 2009–2013 9. A recent assessment of potential sampling bias in MMP indicates these 108 
estimates should be revisited 10. Using 2012 data from a single clinical cohort, the HIV Outpatient Study (HOPS), 109 
in combination with a novel methodology to adjust for possible sampling bias, we demonstrated that MMP may 110 
have undercounted persons in HIV clinical care and that VS prevalence may have been differential among 111 
sampled versus un-sampled persons. Here, we assess the potential effect of sampling bias on MMP-derived VS 112 
estimates during 2009–2013 using data from a large, geographically diverse group of clinical cohorts from the 113 
North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). 114 
Material and methods  115 
NA-ACCORD is the largest multisite collaboration of clinical and interval cohorts in the United States and Canada, 116 
representing over 20 cohorts and 200 clinical care sites. Cohorts contribute data using standardized methods for 117 
patients ≥18 years including demographics, ART prescription, laboratory test results, and dates of primary HIV 118 
clinical visits.  Participants are consented locally and all study activities have been approved by the local 119 
institutional review boards for each site and for Johns Hopkins University School of Medicine 11. 120 
For this analysis, we included nine United States clinical cohorts: Fenway Community Center (MA), the HIV 121 
Outpatient Study, the HIV Research Network (multi-state), Johns Hopkins HIV Clinical Cohort (MD), Retrovirus 122 
Research Center (PR), University of Alabama at Birmingham 1917 Clinical Cohort (AL), University of Washington 123 
HIV Cohort (WA), Veterans Aging Cohort Study (multi-state), and Vanderbilt Comprehensive Care Clinic HIV 124 
Cohort (TN). We chose these cohorts based on the following criteria: being observational in nature, being 125 
located in the United States, and being willing to participate in this analytic activity. For each of the years 2009–126 
2013, we considered adult patients who had ≥1 CD4 test, viral load measurement, or HIV clinical care visit during 127 
January 1 – December 31 as having received HIV care during that year, yielding approximately 30,000 patients 128 
annually. Within each year, we categorized patients as receiving care within the MMP sampling period (January 129 
1 – April 30) or exclusively outside the sampling period. We used individual data on age (categorized as 18–24, 130 
25–34, 35–44, 45–54, and 55+ years) and race/ethnicity (categorized as non-Hispanic white, non-Hispanic black, 131 
Hispanic, and other) as predictors of clinical care receipt exclusively outside the MMP sampling period. Sex at 132 
birth was not associated with care receipt exclusively outside the sampling period. 133 
We applied our previously described cohort-adjustment method 10, which uses principles of indirect 134 
standardization 12 and synthetic estimation 13 to adjust MMP-derived estimates of VS among persons in HIV care 135 
using 2009–2013 NA-ACCORD data. First, separately for each year of NA-ACCORD data, we fit a logistic model 136 
regressing receipt of care exclusively outside the sampling period on age group, race/ethnicity, and the 137 
interaction term age group*race/ethnicity. This model yields estimated odds of care receipt exclusively outside 138 
the sampling period, among all persons receiving care during the year, within each age group*race/ethnicity 139 
stratum. These odds, multiplied by the MMP-derived weighted estimate for number of persons receiving HIV 140 
medical care during the sampling period, yielded adjusted estimates for the number of persons who would not 141 
have been included in the MMP sample despite receiving care during the year. 142 
Next, for each year of NA-ACCORD data, we fit a logistic model regressing VS (viral load <200 copies/mL or 143 
undetectable) at most recent test (last in calendar year) on care receipt exclusively outside the sampling period, 144 
age, race/ethnicity, and the interaction term age*race/ethnicity. We estimated the predicted marginal 145 
prevalence ratios of VS among those receiving care exclusively outside versus inside the sampling period, within 146 
each age*race/ethnicity stratum14. Multiplying these prevalence ratios by MMP-derived VS estimates yielded VS 147 
estimates for persons who would not have been sampled.  148 
We combined these estimates with the original MMP weighted population size estimates for VS, yielding revised 149 
estimates for the total number of persons receiving care and VS, and the percent VS among persons in care. 150 
Point estimates for all outcomes and the 95% confidence intervals for the percent VS were obtained from the 151 
50th (point estimates), 2.5th, and 97.5th percentiles (confidence intervals) of Monte Carlo bootstrap simulations. 152 
Simulations were based on 100,000 runs in which we jointly sampled normal distributions with means and 153 
standard deviations, respectively, defined by the point estimates and the standard errors for all regression 154 
model parameter estimates and MMP weighted frequency estimates. 155 
Results 156 
The cohort-adjustment method yielded weighted population estimates of 355,156 persons VS and 526,850 in 157 
care in 2009 and 441,619 persons VS and 595,807 in care in 2013 (Table 1). Therefore, weighted percentages of 158 
VS among persons in HIV care in the United States were 67% in 2009 and 77% in 2013. The estimated number of 159 
persons in HIV care using the MMP data alone was approximately 20% lower in each year than the estimate 160 
yielded by the cohort-adjustment method and the two data sources together. Similarly, the estimated number 161 
of persons who were VS using the MMP data alone was 15–17% lower in each year than the estimate yielded by 162 
the two data sources together. This pattern held across age and race categories, although the percent 163 
differences for weighted estimates of the numbers of persons in HIV care and virally suppressed were larger in 164 
each year among younger versus older age groups (Supplemental table). 165 
In 2009, VS among persons in HIV care ranged from 60% among non-Hispanic blacks to 70% among 166 
Hispanic/Latinos and 75% among non-Hispanic whites (Table 2). In 2013, VS ranged from 72% among non-167 
Hispanic blacks to 78% among Hispanic/Latinos and 84% among non-Hispanic whites. The VS percentages 168 
generally increased with increasing age group in each year. In 2009, 54% of 18-24 year olds in HIV care were VS 169 
compared to 79% of persons aged 55 years or older. In 2013, 58% of 18-24 year olds in HIV care were VS 170 
compared to 84% of persons aged 55 years or older. The largest percentage increases in VS from 2009 to 2013 171 
were observed among non-Hispanic blacks and among persons aged 25–34 years, while only modest increases 172 
were observed among the youngest and oldest age groups. 173 
 174 
Discussion 175 
Using two large, geographically diverse data sources and a novel methodology, we estimated that the 176 
percentage of persons in HIV clinical care who were VS increased from 67% in 2009 to 77% in 2013. These 177 
estimates are similar to, but lower than, previously published MMP-derived estimates, which indicated VS in this 178 
population increased from 72% (95% confidence interval [CI]: 69–74) in 2009 to 80% (95% CI: 78–83) in 20139. 179 
Conversely, weighted population sizes presented here suggest that the numbers of persons in HIV care and the 180 
number VS were previously underestimated.  181 
The estimated percentage of persons in HIV care who were VS was overestimated due to lower VS prevalence 182 
among persons un-sampled by MMP. NA-ACCORD cohort data indicated persons not receiving care during the 183 
sampling period had lower VS prevalence than those receiving care in the sampling period, which may be 184 
explained by a lower frequency of visits, thus a lower probability of receiving care during the sampling period 185 
and sub-optimal engagement in care.  The finding likely reflects a higher likelihood of any care receipt during the 186 
four-month sampling period due to a higher overall number of care visits during a given year, which is associated 187 
with a higher probability of VS. 15 In other words, the more frequently a patient seeks care during the year, the 188 
more likely they are to be seen during a defined period, regardless of the period used. After making adjustments 189 
for these biases, the 2013 estimate of VS prevalence among persons in HIV care was 77.3%, which is nearly 190 
identical to the 77.2% among persons in NHSS with an indication of HIV care during 2013 (as indicated by >1 191 
reported CD4 or viral load test). 6 192 
The weighted population size for the total number of persons in HIV care in the United States was previously 193 
estimated to be 421,186 in 2009,16 which is 20% lower than the 526,850 estimated using the cohort-adjustment 194 
method to account for un-sampled persons. Similarly, the weighted population size for the total number of 195 
persons in HIV care in the United States who were VS was previously estimated at 301,403 in 2009 (Medical 196 
Monitoring Project, unpublished data), which was 15% lower than the 355,156 presented here. These are 197 
substantially higher weighted population estimates for persons who are in HIV care and VS than those 198 
previously published. If used together with the number of persons living with diagnosed HIV during this period, 199 
this refinement of the weighted population estimates may also provide additional information about how many 200 
persons with diagnosed HIV were receiving care and VS at this time. 17 201 
In 2015, MMP expanded to represent all persons living with diagnosed HIV and now samples directly from the 202 
NHSS register of all persons with diagnosed HIV. The four-month sampling period is no longer used, and HIV care 203 
and treatment outcomes are now estimated for all diagnosed persons. Despite this change, examining bias in 204 
pre-2015 estimates is important for accurate interpretation of current estimates in their historical context. 205 
Historical estimates are used routinely in transmission models and for projecting goals and feasibility of change 206 
in clinical outcomes over time. Additionally, periodic quantitative evaluation of HIV surveillance estimates in 207 
light of temporal changes in population characteristics, clinical practices, and other external factors is good 208 
scientific practice and may help to increase the perceived (and real) reliability of estimates derived from 209 
imperfect data systems with inexact methods. 210 
This analysis has limitations. First, data adjustments can only be applied reliably within strata defined by at most 211 
two factors due to stratum-specific sample sizes 10. We chose age group and race/ethnicity for stratification 212 
because, of the variables we could measure in both NA-ACCORD and MMP, these characteristics were most 213 
strongly associated with both care receipt exclusively outside the sampling period and VS. Notably, sex at birth 214 
was not associated with care receipt exclusively outside the sampling period. Second, we used slightly different 215 
age groups for this analysis compared to age groups used for the previously published MMP VS estimates, which 216 
limits comparability by age between previous and current estimates. However, the age groups used for the 217 
present analysis are nearly identical to those in other national HIV surveillance reports using NHSS data, so this 218 
may facilitate comparisons to, and joint use with, national case surveillance data. Last, while annual estimates of 219 
VS among persons in HIV care from the cohort-adjustment method overlap with confidence intervals for the 220 
previously published MMP estimates, statistical tests cannot be used to compare previous and current estimates 221 
because they rely on data from the same MMP participants. 222 
VS among persons in HIV care is an important indicator of quality of clinical care and of the need for non-clinical 223 
care services that may help close the gap between the number of people in HIV clinical care and the number VS. 224 
These findings are an improvement upon previously published estimates9 and likely bring them closer to truth. 225 
VS increased during 2009–2013, but more work is needed for further gains, particularly among racial/ethnic 226 
minority groups and young people. Careful examination of national surveillance estimates using data 227 
triangulation and novel methodologies can improve the robustness of VS estimates and help to identify groups 228 
for which focused interventions are needed for sustained health improvements and prevention of new 229 
infections.  230 
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Table 1. Weighted estimates for persons receiving HIV medical care and virally suppressed using Medical Monitoring Project data alone versus Medical Monitoring Project and North 
American AIDS Cohort Collaboration on Research and Design data and cohort adjustment method 
 
 2009 2010 2011 2012 2013 
  N (95% CI)  
suppressed 
N (95% CI)  
in care 
% (95% CI) 
suppressed 
N (95% CI)  
suppressed 
N (95% CI)  
in care 
% (95% CI) 
suppressed 
N (95% CI)  
suppressed 
N (95% CI)  
in care 
% (95% CI) 
suppressed 
N (95% CI)  
suppressed 
N (95% CI)  
in care 
% (95% CI) 
suppressed 
N (95% CI)  
suppressed 
N (95% CI)  
in care 
% (95% CI) 
suppressed 
MMP alone               
 301,296 
(274,737, 
328,394) 
421,119  
(385,236, 
457,196) 
 
71.6   
 (69.8, 73.4) 
327,108 
(298,103, 
356,461) 
442,601 
(405,023, 
480,182) 
 
73.9   
  (72.2, 75.6) 
361,421 
(328,679, 
394,540) 
478,380 
(436,439, 
520,172) 
 
75.6     
(73.9, 77.2) 
368,161 
(333,445, 
403,092) 
476,197 
(433,418, 
519,143) 
 
77.3     
(75.8, 78.8) 
393,282 
(360,540, 
426,466) 
490,960 
(451,338, 
530,855) 
80.1     
(78.7, 81.5) 
MMP + 
NA-ACCORD 
              
 355,156 
(323,770, 
387,092) 
526,850 
(482,009, 
571,878) 
 
67.4   
 (65.6, 69.2) 
387,856 
(353,344, 
422,753) 
556,645 
(509,706, 
603,665) 
69.7     
(68.0, 71.4) 
441,107 
(401,342, 
481,295) 
613,220 
 (559,998, 
666,365) 
 
71.9     
(70.3, 73.6) 
441,619 
(400,008, 
483,485) 
595,807 
(542,731, 
649,090) 
 
74.1     
(72.5, 75.7) 
473,693 
(434,227, 
513,686) 
612,966 
(563,724, 
662,608) 
77.3     
(75.8, 78.7) 
Ns represent weighted population totals.  
Percentages are weighted percentages. 
 
Table 2. Cohort-adjusted viral suppression estimates among persons receiving HIV medical care, United States and Puerto Rico, 2009-2013: Medical Monitoring Project and North American 
AIDS Cohort Collaboration on Research and Design 
 
 2009 2010 2011 2012 2013 
  N 
suppressed 
N         
in care 
% (95% CI) 
suppressed 
N 
suppressed 
N           
in care 
% (95% CI) 
suppressed 
N 
suppressed 
N           
in care 
% (95% CI) 
suppressed 
N 
suppressed 
N            
in care 
% (95% CI) 
suppressed 
N 
suppressed 
N            
in care 
% (95% CI) 
suppressed 
Race/ethnicity               
White 137,190  181,928  75.4 (72.7, 78.1) 147,245  190,151  77.5 (74.9, 79.9) 161,464  208,454  77.5 (74.8, 80.1) 171,466  211,872  80.9 (78.8, 83.0) 165,290  197,123  83.9 (81.8, 85.9) 
Black 132,492  220,821  60.0 (57.2, 62.8) 147,231  233,428  63.1 (60.5, 65.7) 164,573  248,071  66.4 (63.8, 68.9) 171,650  249,698  68.8 (66.2, 71.3) 191,412  265,507  72.1 (69.6, 74.6) 
Hispanic 68,369  97,748  70.0 (66.6, 73.3) 73,636  105,819  69.6 (66.0, 73.2) 90,427  123,223  73.4 (70.0, 76.9) 78,052  106,466  73.3 (70.0, 76.7) 96,585  123,170  78.4 (75.7, 81.1) 
Other 16,922  26,313  64.4 (56.3, 73.2) 19,616  27,279  72.0 (65.5, 78.7) 24,481  33,501  73.2 (66.1, 80.1) 20,280  27,721  73.3 (66.4, 79.9) 20,221  27,108  74.7 (68.4, 81.0) 
Age (yrs)               
18 – 24 9,714  17,943  54.3 (44.9, 66.0) 10,140  23,771  42.8 (33.7, 52.8) 10,273  22,363  46.1 (38.9, 53.7) 12,435  22,734  54.8 (47.8, 61.9) 12,915  22,264  58.2 (50.5, 66.3) 
25 – 34 34,979  68,551  51.2 (46.2, 56.0) 39,430  69,442  56.9 (52.0, 61.8) 48,734  78,994  61.8 (57.1, 66.5) 50,745  79,855  63.6 (59.8, 67.4) 51,822  77,742  66.7 (62.7, 70.7) 
35 – 44 89,008  141,034  63.2 (59.7, 66.6) 102,186  146,161  69.9 (66.9, 72.9) 96,515  140,894  68.6 (65.0, 72.1) 88,767  124,973  71.1 (68.2, 73.9) 94,616  126,617  74.8 (71.2, 78.3) 
45 – 54  142,810  200,129  71.4 (68.8, 74.0) 146,172  202,630  72.2 (69.4, 74.8) 175,179  232,568  75.3 (73.0, 77.8) 166,162  218,258  76.2 (73.3, 78.9) 175,380  221,196  79.3 (77.0, 81.6) 
55+ 78,359  99,202  79.0 (75.7, 82.2) 89,818  114,704  78.3 (75.5, 81.0) 110,175  138,471  79.6 (76.6, 82.6) 123,318  149,926  82.3 (79.8, 84.7) 138,784  165,199  84.0 (81.8, 86.2) 
Total 355,156 526,850 67.4 (65.6, 69.2) 387,856 556,645 69.7 (68.0, 71.4) 441,107 613,220 71.9 (70.3, 73.6) 441,619 595,807 74.1 (72.5, 75.7) 473,693 612,966 77.3 (75.8, 78.7) 
Ns represent weighted population totals.  
Percentages are weighted percentages. 
 
